Peter Downie
Head of Unit
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
Germline predisposition has a significant role in paediatric cancer. However, the optimal approach to identifying cancer-causing germline pathogenic variants (GPV) in children, and even the prevalence of GPV among children with cancer, remain unclear. Here we report our findings from a comprehensive survey of GPV in 496 children with poor-prognosis cancer. By integrating tumour and germline molecular profiling we identified GPV in 15.5% of patients, 48.1% of whom had not met clinical genetic testing criteria. Although the cancer type was outside the recognised phenotypic spectrum for 43.7% of reported GPV, 63.2% of these were clinically actionable for cancer risk. Integrated germline-tumour analysis increased the GPV detection rate by 8.5%, and informed germline interpretation in 14.3% of patients with GPV, highlighting the value of integrated analyses. Our findings establish the benefit of broad integrated tumour-germline screening, over phenotype-guided testing, to detect GPV in children with poor prognosis cancers.
Year:
2024
Background Concerns about side effects and treatment interactions and delays may contribute to COVID-19 vaccine hesitancy amongst cancer patients. In the large prospective SerOzNET study of COVID-19 vaccine response in children and adults with cancer, vaccine beliefs, physician- and participant-reported adverse events (AE), treatment interruptions and quality of life (QoL) were studied. Methods The Australian experience with COVID-19 gave a unique opportunity to study vaccination response in an infection- and vaccine-naïve cancer population. Patients with current or recent solid or hematological malignancy, aged five and over, had serial assessments prior to and following multiple SARS-CoV-2 vaccinations. Electronic surveys were administered at baseline and after first, second and third doses to collect vaccine beliefs (Oxford Confidence and Complacency Scale), patient-reported toxicity and QoL (QLQC30 or PedsQL). Detailed toxicity data were collected at clinic visits and from medical records. Results A total of 1385 vaccination doses were administered (93% BNT162b2), with at least 1 dose received by 499 patients, of whom only seven had known prior COVID-19 infection. Vaccine related beliefs were generally positive. There were no vaccine-related interruptions to cancer therapy. AE occurred in 95% of recipients, with the highest ranked severity being mild in 36% and moderate, severe or serious in 31%, 19% and 6% respectively. QoL showed no significant deterioration post-vaccination. Conclusion This robust dataset provides evidence regarding safety and tolerance of SARS-CoV-2 vaccination in adults and children with cancer. Patients and families can be reassured that rates of AEs are comparable to the general population and do not impact delivery of cancer therapy or QoL.
Year:
2024
Year:
2023
Collaborators (13)
Jordan R Hansford
Oncologist
University of Melbourne
Eva Segelov
MONASH UNIVERSITY
David Ziegler
Professor
University of New South Wales
Paul Ekert
Group Leader, Translational Tumour Biology
Children's Cancer Institute Australia
Nicholas Gottardo
University of Western Australia
Stephen Opat
Monash Health
Mark Cowley
Conjoint Professor
University of New South Wales
Vanessa Tyrrell
Co-Head of Division - Peronalised Medicine
Children's Cancer Institute Australia
Andrew Moore
Associate Professor
University of Queensland
Vivienne Milch
Professorial Fellow
Flinders University
Wayne Nicholls
Clinical Director and Associate Professor
University of Queensland
Chelsea Mayoh
Children's Cancer Institute Australia
Marion Mateos
University of New South Wales
Make your next move.
Prepare your application
Review drafts before you send them.